BREAKING NEWS= TP RM13.20

Latest TP Given BY CIMB on SUPERMAX- TARGET PRICE- RM13.20

Pfizer’s CEO hasn’t gotten his Covid vaccine yet, saying he doesn’t want to cut in line

PUBLISHED MON, CNBC. DEC 14 202010:02 AM EST

Pfizer CEO Albert Bourla hasn’t received his company’s Covid-19 vaccine shot yet, saying Monday he and other executives will not “cut the line” as U.S. officials kick off a massive effort to distribute the vaccine across the country.

He is hesitant. I wonder why.

THE IBS AND THEIR COHORTS CAN MANIPULATE THE SHARE PRICE BUT CANNOT MANIPULATE THE ROCK SOLID FUNDAMENTALS OF SUPERMAX.

LOOK AT MERCATOR - UP 21% YESTERDAY-

COVID IS OUT OF CONTROL IN USA & EUROPE- LOCKDOWNS IMMINENT.

THE BEST STOCK IN BURSA

EASILY RM 8-00 BY FRIDAY.

There will be lockdown in USA and Europe as Covid is out of control, The rollout of vaccines has brought about a sense of false security.

GLOVES set-to SURGE- World suffering a Masssive shortage of GLOVES.

Posted by Newbusybody > Dec 15, 2020 10:38 PM | Report Abuse

Why is mercator 20% up. Whats the latest news?

How Long Does Pfizer Vaccine Protect You?

Answer- Still Not Clear How Long.
----------------------------------------
Once someone is vaccinated for COVID-19, their body should naturally develop antibodies that correspond with the virus and ward off future infection, but it’s still not clear how long those antibodies will last.

“The only thing we can tell is what we can learn from natural infection,” said Dr. Maria Elena Bottazzi of Baylor College of Medicine, who helped develop a COVID-19 vaccine currently being tested in India.

According to the Centers for Disease Control and Prevention, cases of reinfection are rare but some have been reported, and studies on the topic are ongoing.

“By the very definition of a question like that, only time will tell,” Dr. Viscidi said. “After you get a vaccine, you produce a lot of antibodies, and they start to go down …. Depending on the vaccine, they can go down more or less rapidly.

USA & EUROPE HEADED FOR LOCKDOWN- as cases and fatalities SURGE

Jim Cramer says stay-at-home trade is back on — ‘Lockdown is where we’re headed’

https://www.cnbc.com/2020/12/14/cramer-says-stay-home-trade-is-back-lo...

PAT for Q2 estimated at RM1 billion
-----------------------------
Posted by peterwkc > Dec 15, 2020 11:54 AM | Report Abuse

What is the projected PAT for Q2?

ASP Still on the Rise- maybe till 2022.
-------------------------------------

“2021 is a foregone conclusion — that profit will be exceptional and the same order backlog has flowed into 2022 with no indication of ASPs subsiding yet,” it said.

TA Securities

Share price weakness - An opportunity to accumulate.
------------------------------------------------------
Hong Leong Investment Bank (HLIB) Research said in a report today it had an "overweight" call for the glove sector as glove makers' share prices had come off even as Covid-19 cases would continue to rise in 2021.

Top Glove is among its top picks as it believes concerns over negative repercussions from Covid-19 vaccines seem to be overplayed for a number of other reasons besides rising infections, namely that gloves would still be needed to administer vaccines, and post-pandemic glove demand, when it happens, would still be structurally higher than pre-pandemic levels due to higher hygiene awareness.

“We see recent share price weakness as an opportunity to accumulate,” it said.

SUPER MAX will be in the KLCI index this coming Monday (21st ).

This Friday there will be a portfolio rebalancing by big Funds- They have no choice but to add SUPERMAX to their Portfolio.

Just 3 days to go before we see a massive surge in SUPERMAX.

Funds are just accumulating and waiting for explosive day for SUPERMAX.


WHY SELL NOW???

Security Commission should investigate JP Morgan
---------------------------------------------------
Why should JP Morgan have downgraded Top Glove and Hartalega when there is a continuous increasing demand for medical gloves due to Covid 19 pandemic.

Due to Covid 19 pandemic the demand for medical gloves far exceeds supply and all the glove makers can easily increase their selling prices to make more and more profit. That is why Top Glove can report such an unprecedented profit. Until the pandemic is completely under control, the demand for medical gloves will continue to exceed supply and all the glove makers will continue to increase their selling prices to make more and more profit.

Securities Commission should examine the validity of JP Morgan’s reasons for downgrading Top Glove and Hartalega.

SC should also find out whether JP Morgan or its collaborators sold Top Glove and Hartalega at much higher prices before it downgraded them.

Since JP Morgan said that these 2 glove stocks are no good, whether JP Morgan or its collaborators will sell all their current holdings in Top Glove and Hartalega.

SC should also watch closely whether JP Morgan or its collaborators will buy Top Glove and Hartalega when the share prices are cheaper.

INTCO MEDICAL- SURGE TO ALL TIME HIGH MOMENTS AGO- DUE TO WORLD SHORTAGE
-------------------------------------------------------

Intco Medical Technology Co Ltd
SHE: 300677
163.12 CNY +4.12 (2.59%)
15 Dec, 9:51 am GMT+8 · Disclaimer

GLOVES IN BURSA WILL RECOVER & CONTINUE TO RISE AS WORLD IS FACING SEVERE SHORTAGE OF MEDICAL GLOVES.

THE PANDEMIC WILL FORCE MORE LOCKDOWNS IN USA & EUROPE- AS COVID IS OUT OF CONTROL.

INVESTORS WILL FLOCK TO GLOVES AGAIN
--------------------------------------------

Asian stocks dip as investors curb vaccine enthusiasm or rather over optimism

Economy18 minutes ago (Dec 14, 2020 08:20PM ET)


NEW YORK (Reuters) - Asian stocks came under pressure on Tuesday following a mixed Wall Street session, as concerns about increasing COVID-19 deaths, infections and lockdowns overshadowed optimism about the start of coronavirus vaccinations.

Australian S&P/ASX 200 lost 0.12% in early trading while {{178|Japan's NiNikkei 225 futures fell 0.13%. E-mini futures for the S&P 500 rose 0.21%.
The lackluster start to the Asian day comes after the S&P 500 closed down 0.4%, the Nasdaq Composite gained 0.5% and the Dow Jones Industrial Average hit a record high but fell back 0.6% for the day.

The first U.S. vaccination was given to an intensive care nurse on Monday, the same day the country passed the grim milestone of 300,000 lives lost.
COVID-19 deaths in the U.S. are occurring at a record rate 2,462 per day on a seven-day average, according to a Reuters count.

Meanwhile, new waves of the pandemic forced Germany, the Netherlands and London back to stricter lockdowns while cases in Japan and South Korea also surged.

Some traders said markets have already factored in optimism about vaccines.
"We've been trading off the same vaccine headlines for three or four months," said Dennis Dick, a trader at Bright Trading LLC. "This market is 100% relying on this vaccine."

INTCO MEDICAL CO LTD - CLOSED AT ALL TIME HIGH @ TODAYS CLOSE.
-------------------------------------------
Intco Medical Technology Co Ltd
SHE: 300677
159.00 CNY +10.50 (7.07%)
14 Dec, 4:29 pm GMT+8 ·

The world have to live with GLOVES- Across a wide range of Sectors.

A Structural shift for GLOVES- the new norm.

Take advantage of the cheap sale going on in BURSA.

SUPERMAX seeks go ahead for UK and European headquarters in Peterborough
---------------------------------------------------------------------------
A medical gloves supplier is seeking the go ahead for a multi-million pound European head office development in Peterborough.

Supermax Healthcare, based in Titan Drive, Fengate, has submitted a planning application to Peterborough City Council for a new headquarters, office, production and distribution facility at Kingston Park, in Flaxley Road.

If approved, the new three-storey facility would serve as the UK and European headquarters and distribution centre for the Supermax Group, which produces up to 17.6 billion gloves per year - about 11 per cent of the world’s latex examination gloves

The application shows the firm, which has 35 staff, plans to create 1,306sqm of office space plus 4,057sqm for storage and distribution on a 1.14 hectare site.



SUPERMAX - THE LEADER IN EUROPE.



By Paul Grinnell. The Telegraph
Wednesday, 9th December 2020,

China's largest GLOVES company-

INTCO MEDICAL HIT ALL TIME HIGH TODAY.
----------------------------------------------
Intco Medical Technology Co Ltd
SHE: 300677
155.58 CNY +7.08 (4.77%)

OUR GLOVES COUNTERS GETTING BASHED

CLEARLY BEING MANIPULATED BY IBs

Great article , thanks for sharing.

Supermax will rise like a Phoenix after the Gross Manipulation by IBs.

Fundamentals very much intact, in fact improving each day.

Recovery stocks is the current flavour that won't last long as earnings for the next few years will be very weak.

Investors will return to GLOVES.

Just be patient.

Chill Bros- Here's Covid on a lighter vein.

Medical experts in Dublin today were asked if it is time to ease the COVID lock down:
Allergists were in favour of scratching it, but Dermatologists advised not to make any rash moves.
Gastroenterologists had a sort of a gut feeling about it, but Neurologists thought the government had a lot of nerve.
Obstetricians felt certain everyone was labouring under a misconception, while Ophthalmologists considered the idea short-sighted.
Many Pathologists yelled, "Over my dead body!" while Paediatricians said, "Oh, grow up!"
Psychiatrists thought the whole idea was madness, while Radiologists could see right through it.
Surgeons decided to wash their hands of the whole thing and pharmacists claimed it would be a bitter pill to swallow.
Plastic Surgeons opined that this proposal would "put a whole new face on the matter."
Podiatrists thought it was a step forward, but Urologists were pissed off at the whole idea.
Anaesthetists thought the whole idea was gas, and Cardiologists didn’t have the heart to say no.
In the end, the Proctologists won out, leaving the entire decision up to the assholes in politics.... and the political assholes made a mess of it ....

In rare media rebuke, Top Glove demands accurate reporting amid Covid-19 flare

TheEdge Sun, Dec 13, 2020
----------------------------------------------------------------------------

KUALA LUMPUR (Dec 13): In a rare rebuke to the media, Top Glove Corp Bhd urged reporters to honour the principles of ethical journalism by verifying the news they publish about the rubber glove manufacturer to enable readers to have access to accurate, balanced and transparent reporting amid a rising number of Covid-19 cases.

The rebuke followed a video clip, which Top Glove claimed as misleading and damaging to the company’s reputation.

In a statement yesterday, Top Glove said the company was responding to a video published by VICE News on its YouTube channel on Thursday titled "This PPE Factory Isn't Protecting Its Workers Against COVID".

Top Glove claimed issues raised in the video "are thoroughly misleading and damaging to the company’s good-standing reputation".

"Please be informed, too, that the claim of workers having to go through three medical examinations before coming to Malaysia to work for Top Glove is false. A worker would go through a maximum of two medical examinations. Each medical examination is valid for two months, and it is an exceedingly rare case that a worker is not deployed within two months,” Top Glove claimed.

"As of Dec 8, approximately 94% of our workers who had undergone testing were ready to resume work after being cleared of Covid-19. This included workers who had tested negative and undergone the stipulated quarantine period from close contact tracing,” the company said.

Top Glove said it stands by the hard work and dedication of its team in ensuring the company continues to deliver high-quality and essential medical gloves to first responders and frontliners all over the world in a timely and efficient manner.

The numbers of Covid-19 cases have risen globally. In South Korea, for example, news reports, quoting the Korea Disease Control and Prevention Agency, indicated that the nation saw 1,030 new coronavirus infections today, the second daily record in a row as the country that had initial success controlling Covid-19 battled a harsh third wave.

Of the new cases, 1,002 were locally transmitted, and the figure brought the total to 42,766 infections with 580 deaths, Reuters reported.

In Germany, it was reported that data from the Robert Koch Institute for infectious diseases showed today the number of confirmed coronavirus cases in the country had increased by 20,200 to 1,320,716.

The country's Covid-19 death toll had risen by 321 to 21,787, Reuters reported the tally as showing.

Chris Whitty warns coronavirus vaccination might be needed 'annually' if virus mutates
----------------------------------------------------------------------
CHRIS WHITTY has warned some people may need to be vaccinated again should the impact of the jab wane with time or the coronavirus mutate again.

Dec 9, 2020 | UPDATED: 12:55, Wed, Dec 9, 2020

Professor Chris Whitty said it remains unclear how long the effects of the coronavirus vaccine will last and whether people will need to be re-vaccinated on an annual basis to ensure they are protected. The Chief Medical Officer for England insisted more data on the vaccine will be needed to reach a conclusion on the need for repeated vaccinations but noted two scenarios may require the vaccination scheme to expand to include renew the vaccine. Speaking in front of the Science and Technology Committee and Health and Social Care Committee, Prof Whitty said: "We don't know how long...we know this is a very good vaccine to provide short to medium-term protection.

"We don't know how long it lasts. It might last for a very long time, it might last for nine months.

"I think it's more likely to be somewhere between those two.

"And in that case, we might have a case where we are in a position to re-vaccinate, particularly people who are most vulnerable."

He also warned a potential mutation in the coronavirus structure could force scientists to develop a whole new vaccine and result in a new wave of vaccinations across the country.

Debunking JP Morgan’s alarmist report on Top Glove and the Glove Sector
--------------------------------------------------------------------------
Author: sutp | Publish date: Sat, 12 Dec 2020, 8:46 PM

In yesterday’s Edge (11/12/2020), we get another article from an investment bank, peddling the same mantra of over-supply of gloves. JP Morgan is a highly respected financial institution. I am surprised and disappointed that it would lend its name to a report that is largely a seat-of-the-pants analysis, with spurious claims and arguments without any concrete supporting data.

Let me list down its fake claims and speculative hypotheses and debunk them one by one:

JPM: Global testing trends have plateaued
Rebuttal: With cases soaring to meltdown levels, how is it possible for testing to have plateaued?


JPM: Testing trends have started to trend downwards from their peaks since the end of September. Therefore glove prices have peaked.
Rebuttal: Top Glove has just reported that ASP will be 30% higher in 2nd quarter


JPM: The expectation that the use of gloves per capita would double post Covid-19 is "overly optimistic", given global population growth is substantially slower
Rebuttal: JPM is equating growth in per capita use of gloves post pandemic to world population growth, which is about 1.1%. Isn’t this is ridiculous? Top Glove sales have been growing at a rate of more that 13% p.a. even before the covid pandemic. After the pandemic, the world will become more health and hygiene conscious and it is entirely plausible that per capita consumption will be high.


JPM: Glove production capacity is expected to grow 87% in the next three- to five years
Rebuttal: JPM claims that an 87% growth in production capacity (if true) over 5 years will lead to over-supply. But 87% growth over 5 years is only 13.3% per year compounded. Top Glove’s CAGR for the last 5 years was 23.6% and the 4 years before the Covid pandemic was 13.5%.


JPM: We can take a leaf from the crude palm oil industry which saw a decade of oversupply post a supernormal cycle in the early 2000s
Rebuttal: Comparing glove with palm oil is again nonsense. Palm oil oversupply is unavoidable as the FFB (which is perishable) from the increased planted acreages have to be converted to oil. But glove manufacturers can shut down production lines when demand drops. So increased capacity does not have to mean oversupply.

And glove is not a commodity like palm oil. The health and medical segment accounts for 69.4% of global glove sales and gloves for this segment command a premium price as quality is crucial. Hence, buyers are less likely to change suppliers and concomitantly price is also less likely to drop. Therefore, the established large glove supplies will have a great competitive advantage over new entrants.


JMP: Additionally, glove makers' profitability is expected to be negatively affected by higher raw material prices and rising labour costs.
Rebuttal: Raw material and labour cost increases is a fact of life and applies to almost all manufacturing industries. And as cost increases applies to all competing companies, the increased costs are usually passed on to the consumer. This will not affect profitability. By bringing up the cost issue, which is a non-issue, JPM is clearly trying to stretch its argument to justify the paring the fair value of Top Glove’s share price to RM3.50.


JPM: Retail and foreign participation are at all-time highs. It is thus difficult to find incremental dollars to drive this sector higher
Rebuttal: There is no sense to this statement. Investors come and go; buy and sell. Money will always chase profitable growth stocks when negative sentiments are proven wrong


JPM: Top Glove is using cash to support capacity growth instead of debt
Rebuttal: Yes ROE will be higher with use of debt but ROE is already very high anyway. And prudence in using surplus cash is not necessarily bad.


This JPM article is a very poorly reasoned one. It is obvious that it is another shameful attempt to spook glove investors into selling and thereby creating buying opportunity for the fund managers in JPM

Debunking JP Morgan’s alarmist report on Top Glove and the Glove Sector
--------------------------------------------------------------------------
Author: sutp | Publish date: Sat, 12 Dec 2020, 8:46 PM

In yesterday’s Edge (11/12/2020), we get another article from an investment bank, peddling the same mantra of over-supply of gloves. JP Morgan is a highly respected financial institution. I am surprised and disappointed that it would lend its name to a report that is largely a seat-of-the-pants analysis, with spurious claims and arguments without any concrete supporting data.

Let me list down its fake claims and speculative hypotheses and debunk them one by one:

JPM: Global testing trends have plateaued
Rebuttal: With cases soaring to meltdown levels, how is it possible for testing to have plateaued?


JPM: Testing trends have started to trend downwards from their peaks since the end of September. Therefore glove prices have peaked.
Rebuttal: Top Glove has just reported that ASP will be 30% higher in 2nd quarter


JPM: The expectation that the use of gloves per capita would double post Covid-19 is "overly optimistic", given global population growth is substantially slower
Rebuttal: JPM is equating growth in per capita use of gloves post pandemic to world population growth, which is about 1.1%. Isn’t this is ridiculous? Top Glove sales have been growing at a rate of more that 13% p.a. even before the covid pandemic. After the pandemic, the world will become more health and hygiene conscious and it is entirely plausible that per capita consumption will be high.


JPM: Glove production capacity is expected to grow 87% in the next three- to five years
Rebuttal: JPM claims that an 87% growth in production capacity (if true) over 5 years will lead to over-supply. But 87% growth over 5 years is only 13.3% per year compounded. Top Glove’s CAGR for the last 5 years was 23.6% and the 4 years before the Covid pandemic was 13.5%.


JPM: We can take a leaf from the crude palm oil industry which saw a decade of oversupply post a supernormal cycle in the early 2000s
Rebuttal: Comparing glove with palm oil is again nonsense. Palm oil oversupply is unavoidable as the FFB (which is perishable) from the increased planted acreages have to be converted to oil. But glove manufacturers can shut down production lines when demand drops. So increased capacity does not have to mean oversupply.

And glove is not a commodity like palm oil. The health and medical segment accounts for 69.4% of global glove sales and gloves for this segment command a premium price as quality is crucial. Hence, buyers are less likely to change suppliers and concomitantly price is also less likely to drop. Therefore, the established large glove supplies will have a great competitive advantage over new entrants.


JMP: Additionally, glove makers' profitability is expected to be negatively affected by higher raw material prices and rising labour costs.
Rebuttal: Raw material and labour cost increases is a fact of life and applies to almost all manufacturing industries. And as cost increases applies to all competing companies, the increased costs are usually passed on to the consumer. This will not affect profitability. By bringing up the cost issue, which is a non-issue, JPM is clearly trying to stretch its argument to justify the paring the fair value of Top Glove’s share price to RM3.50.


JPM: Retail and foreign participation are at all-time highs. It is thus difficult to find incremental dollars to drive this sector higher
Rebuttal: There is no sense to this statement. Investors come and go; buy and sell. Money will always chase profitable growth stocks when negative sentiments are proven wrong


JPM: Top Glove is using cash to support capacity growth instead of debt
Rebuttal: Yes ROE will be higher with use of debt but ROE is already very high anyway. And prudence in using surplus cash is not necessarily bad.


This JPM article is a very poorly reasoned one. It is obvious that it is another shameful attempt to spook glove investors into selling and thereby creating buying opportunity for the fund managers in JPM

HEALTHCARE: SUPERMAX MAKING SUPER PROFITS
======================================
The Edge Malaysia

December 12, 2020 09:00 am +08

HIGHEST RETURNS TO SHAREHOLDERS OVER 3 YEARS
------------------------------------------------------------

Supermax Corp Bhd has walked away with The Edge Billion Ringgit Club (BRC) award for highest returns to shareholders over three years in the healthcare sector.

Looking at its share price performance, it is not hard to fathom how the rubber glove maker, which has also ventured into contact lens manufacturing, won the award.

This year has been a spectacular one for the disposable glove industry globally. The companies are making super profits due to the surge in demand for personal protective equipment, including rubber gloves, as a result of the Covid-19 pandemic. Given the rosy earnings prospects, their share prices have soared to the highest level ever.

The craze for rubber glove stocks has lifted Supermax’s share price out of the doldrums and propelled it north. And the rally is the strongest ever it has had since listing in 2000.

The company’s adjusted share price jumped from 90 sen on June 30, 2017, to RM8 on June 30, 2020 — a meteoric rise. Its share price rally continued, climbing to the peak of RM11.90 on Aug 6, as its market capitalisation reached an all-time high of RM30.71 billion. In the BRC award’s 2020 three-year period, Supermax provided a stunning total return of 106.8% to shareholders.

According to Bloomberg, there is upside potential for Supermax’s share price based on the consensus target price of RM12.39 after the release of its third-quarter results.

TP RANGED FROM RM 11.80 to RM16.50
--------------------------------------
All nine research analysts who cover Supermax have recommended their clients to buy the stock, with target prices ranging from RM11.83 to RM16.50.

Suffice to say, among the shareholders of Supermax, nobody is happier than its founder and major shareholder Datuk Seri Stanley Thai Kim Sim, who was not even a billionaire before the pandemic.

It is estimated that Thai’s equity interest of 38.04% in Supermax is worth about RM9.28 billion today. In comparison, the glove tycoon’s net worth was RM672.59 million at end-2009.

Supermax’s profit was already on the rise pre-pandemic for the three-year period between the financial year ended June 30, 2017 (FY2017) and FY2019. The glove maker achieved profit after tax of RM70.29 million in FY2017, which grew to RM110.14 million in FY2018 and RM123.11 million in FY2019. Annual revenue expanded from RM1.126 billion in FY2017 to RM1.304 billion in FY2018 and RM1.538 billion in FY2019.

BIG LEAP IN EARNINGS
-----------------------------
For FY2020, Supermax witnessed its biggest leap in earnings — its net profit jumped more than four times to RM525.58 million from RM123.11 million in FY2019.

In view of the abnormally strong demand for rubber gloves, analysts are expecting an even more powerful profit growth in FY2021. The consensus forecast is for Supermax’s net profit to more than triple to RM1.718 billion in FY2021.

In an Oct 4 report, Kenanga Research analyst Raymond Choo Ping Khoon points out that Supermax has dual-stream incomes from manufacturing and distribution, as both divisions could provide higher margins.


GROWING ENQUIRIES FROM GOVT AGENCIES
----------------------------------------------
“Supermax is getting enquiries from foreign government agencies, non-governmental organisations, retailers and restaurant chains. Amplifying the pent-up demand, buyers are paying between 30% and 50% deposits in advance to secure glove supply and timely delivery,” he writes.

Choo has an “outperform” call on Supermax, with a target price of RM12.75.

Supermax had been in a net debt position of more than RM200 million over the years. With its ballooning cash coffer now, this is a thing of the past. The rubber glove maker was sitting on a net cash position of RM852.7 million as at June 30 this year, thanks to the soaring sales.

JP MORGAN fined US920m or RM 3.8 billion for spoofing in USA in September 2020.
----------------------------------------------------------
Spoofing is an act of creating buy sell orders to create false impression for demand and supply to manipulate price.

Here in Malaysia they are indulging in gross manipulation of Gloves stocks.

Hope Bursa and SC are closely monitoring them.

JP MORGAN FINED FOR MANIPULATION
----------------------------------------

JPMorgan to pay US$920 mil settlement for ‘spoofing’ markets
Reuters

NEW YORK: JPMorgan Chase & Co has agreed to pay more than US$920 million and admitted to wrongdoing to settle federal US market manipulation probes into its trading of metals futures and Treasury securities, the US authorities said on Tuesday.

The landmark multi-agency settlement lifts a regulatory shadow that has hung over the bank for several years and marks a signature victory for the government’s efforts to clamp down on illegal trading in the futures and precious metals market.

JP MORGAN-FINED US920 million for MANIPULATION
------------------------------------------
JPMorgan Chase & Co has agreed to pay more than US$920 million and admitted to wrongdoing to settle federal US market manipulation probes into its trading of metals futures and Treasury securities, the US authorities said

MERCK -worlds leading authority on vaccine development- Comments on Vaccine.
--------------------------------------------------------------------

Ken Frazier, CEO of pharma giant Merck and a leading global authority on vaccine developments, cautioned on the danger of rushing the current vaccine development process. Here is what he said (from the horse’s mouth) which our government and all of us must listen carefully:

“Well, first of all, it takes a lot of time… Why?... it requires a rigorous scientific assessment. And here we didn’t even understand the virus itself and how it affects the immune system… what we are hoping to be able to do is to create a vaccine that can be both safe and effective and can be durable. Those are three different issues. What worries me the most is that public is so hungry, so desperate to go back to normalcy, that they are pushing us to move things faster and faster.

“There are a lot of examples of vaccines in the past that have stimulated the immune system, but ultimately didn’t confer protection. And unfortunately, there are some cases where it stimulated the immune system and not only it didn’t confer protection, but actually helped the virus invade the cell because it was incomplete in terms of immunogenic properties. We have to be very careful. In the last quarter century, there have only been seven, truly new vaccines introduced globally at the clinical practice… We have been trying to get an HIV vaccine since the 1980s and we’ve been unsuccessful.

“When people tell the public that there’s going to be a vaccine by the end of 2020, they do a grave disservice to the public. We don’t want to rush the vaccine before we’ve done rigorous science. We’ve seen it in the past, for example, with the swine flu, that that vaccine did more harm than good. We don’t have a history of introducing vaccines quickly in the middle of a pandemic.”

JP MORGAN-FINED US920 million for MANIPULATION
------------------------------------------
JPMorgan Chase & Co has agreed to pay more than US$920 million and admitted to wrongdoing to settle federal US market manipulation probes into its trading of metals futures and Treasury securities, the US authorities said

JP MORGUE- WORLDS LEADING MARKET MANIPULATOR
----------------------------------------------
Posted by glovefinish > Dec 12, 2020 11:14 AM | Report Abuse

Don't forget J.P Morgan is one of the leading worldwide analyst institution that a lot of funds including foreign funds are to refer to its target price and analysis as base for adjusting and allocating fund for investment.

JP MORGAN FINED FOR MANIPULATION
----------------------------------------

JPMorgan to pay US$920 mil settlement for ‘spoofing’ markets
Reuters - September 30, 2020 11:16 AM

NEW YORK: JPMorgan Chase & Co has agreed to pay more than US$920 million and admitted to wrongdoing to settle federal US market manipulation probes into its trading of metals futures and Treasury securities, the US authorities said on Tuesday.

The landmark multi-agency settlement lifts a regulatory shadow that has hung over the bank for several years and marks a signature victory for the government’s efforts to clamp down on illegal trading in the futures and precious metals market.

Latest Report by Arizton dated 10th December 2020.

1-Rubber Gloves Market Size to Reach Revenues of around USD 58 Billion by 2026

2-The global rubber gloves market expected to grow at a CAGR of over 13% during the period 2020−2026.
---------------------------------------------------------------
Key Highlights Offered in the Report:Key Drivers and Trends fueling Market Growth:

Onset in Pandemic Diseases

Growth in Cleanroom Technology

Concern Towards Personal Hygiene

Growing Medical and Surgical Applications

Brands like Kossan and Hartalega are highly concentrated in nitrile segment where the global consumption is expected to reach over 275 billion pieces by 2026.

The powder free forms are the future of rubber gloves industry that are backed up by supportive government regulations and sustainability goals and initiatives.

Non-medical segment is expected to account for around 57% of the revenue share by 2026 with promising applications in food, chemical, and pharma industries.

The presence of talented surgeons, affordable costs, and other insurance incentives are driving the medical tourism and surgical gloves market in Brazil, Argentina, Costa Rica and Singapore.

North America is expected to grow over 9% in terms of volume consumption following the rise in per capita consumption during the pandemic in 2020.

Japan is expected to generate an incremental revenue of USD 1.7 billion by 2026 owing to the aging population, lucrative demand in automotive, and cleanroom segments.

Despite losing a share to the nitrile segment, the natural rubber gloves segment accounted for over 40% of the total volume in 2020. North America is expected to continue its dominance during the forecast period, anticipating an incremental growth of over 37 billion units.

Disposable gloves are fundamental in medical and healthcare institutions. The impact of COVID-19 has accelerated the production of disposable gloves significantly across the world.

About Arizton:

Arizton Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world.

https://finance.yahoo.com/news/rubber-gloves-market-size-reach-160000542.html

Top Glove just reported EPS 29.64 sen. Its previous quarter was 5.32 sen, an increase of 5.6 times. Supermax reported EPS 30.58 sen for its 1st quarter ending September. Its next quarter ending December will be announced in Mid-January. Based on Top Glove’s profit growth rate, Supermax’s profit should be another new record high. All serious investors must wait patiently for another 5 weeks.

Intco Medical Tec. Co Ltd- Closed at All Time High( ATH) today.
-------------------------------------------

Intco Medical Technology Co Ltd
SHE: 300677
141.00 CNY +2.07

Soon SUPER will be turbo charged and breach its ATH of Rm12.20 in late January 2021.

SUPERS admission to the KLCI index and fantastic quarterly results estimated PAT of RM1.billion

Will be the most powerful catalyst.

Mercator flying to the moon after V day ( Vaccine day) is declared in the UK earlier today.
----------------------------------------------------------------
Mercator Medical SA
WSE: MRC
492.00 PLN +32.00 (6.96%)
8 Dec, 12:59 pm GMT+1 · Disclaimer

Who says Vaccine & Gloves can't co -exist ?

I feel the relationship is symbiotic.

GLOVES sector is expected to undergo a structural step up in demand post pandemic.

Correct Uncle ! - Supermax is a GOLDEN Duck and not a lame duck.

This is what you call a SUPER stock.

Set to SHINE in 2021.

A TP RM15 shouldn't be a problem.

Astute investors should see this glaring opportunity
---------------------------------------------------

Covid 19 pandemic is affecting every listed companies except medical gloves, medical product for the virus prevention and a few other products. As a result, the demand for medical gloves far exceeds supply and all the glove makers have been increasing their selling prices to make more and more profit.

For some mysterious reasons all the glove stocks have been dropping quite rapidly in the last few days. All the price charts are showing down trend which are encouraging more sellers. Even our famous Mr Ooi Teck Bee would not recommend to all his subscribers to buy glove stocks because they do not comply with his golden rule namely technical and financial analysis.

No wonder statistical record shows that 80 % of all the investors lose money, 10% can break even and only 10% can make money. Currently due to Covid 19 pandemic, there must be more losers and fewer winners.

Glaring opportunity

Supermax reported EPS of 30.58 sen for its 1st quarter ending September. Its previous quarter EPS was 15.29 sen. It made 100% more than its previous quarter because the company could easily increase its selling price for its gloves during the pandemic.

Its 2nd quarter ending December its EPS should be more than 30.58 sen. Even if I assume that its 2nd quarter EPS is the same as its 1st quarter its earning for half year will be 61.2 sen.

It will announce its 2nd quarter result in mid-January 2021 which is about 5 weeks from now.

Its last closing price was Rm 7.70 per share.

All investors should be able to foresee 5 weeks ahead that Supermax is so much undervalued.

This opportunity is glaring in front of us. All investors should see this glaring opportunity to make more money.

by Uncle KYY

U.S. faces nitrile glove shortage ahead of national COVID-19 vaccination effort
----------------------------------------------------------------------

The U.S. Government Accountability Office found that "availability constraints continue with certain PPE" including nitrile gloves.

Gloves ASP - set to surge till end of 2021 - at least

Gloves sector will definitely be the darling of investors, again.- as fundamentals are set to strengthen further- thanks to vaccines.

@joyride- I fully agree with your brilliant comments/analysis. Yup, just hold on to SUPERMAX and enjoy the joyride early next year.(late January onwards).
-----------------------------
So i think this is what is going to happen.
The glove sector will NOT see anymore increase this year. Supermax would most likely trade within the RM8-9 range.

However 2021 is a new year. We will definitely see the dramatic move of Supermax. My reading of the charts indicate that sometime around January 21 next year or thereabouts, we could see the rotation play of the glove sector. It might be linked with news of hiccups with the vaccine or something like that. But the long and short of it is, we need to hold on to our shares at least until end of January 2021 to see the kind of movement we have been waiting for. I am holding mine.

WHO warns Covid reinfections may occur as data suggests antibodies wane
PUBLISHED FRI, DEC 4
----------------------------------------------------------------
1-World Health Organization officials on Friday warned that recent data suggest that, though it is rare, people who were once infected with the coronavirus could be infected again.

2-The WHO’s Dr. Mike Ryan said that emerging data suggests “protection may not be lifelong” after someone’s infected with Covid-19.

3-Maria Van Kerkhove, head of the WHO’s emerging diseases and zoonosis unit, said ongoing research indicates an immune response may last for six months or longer.

“We have seen the number of people infected continue to grow, but we’re also seeing data emerge that protection may not be lifelong, and therefore we may see reinfections begin to occur,” Dr. Mike Ryan, executive director of the WHO’s health emergencies program, said during a press briefing at the organization’s Geneva headquarters. “So the question is: What are the levels of protection in society?”

https://www.cnbc.com/2020/12/04/who-warns-covid-reinfections-may-occur-as-data-suggests-antibodies-wane.html

Supermax in, KLCCP Stapled Group out of FBM KLCI
---------------------------------------------------
Syahirah Syed Jaafar

KUALA LUMPUR (Dec 3): Supermax Corp Bhd has been added to the FTSE Bursa Malaysia KLCI, following the semi-annual review of the FTSE Bursa Malaysia Index Series today.

In a statement by Bursa Malaysia today, it said KLCC Property Holdings Bhd and KLCC REIT (KLCCP Stapled) will be removed from the index.

The index series is reviewed semi-annually in accordance with the index ground rules.

All constituent changes will take effect at the start of business on Dec 21.

Coronavirus will be with us forever, claims Jonathan Van-Tam

--------------------------------------------------
Jonathan Van-Tam encourages Britons to practice the 'three Cs' - closed spaces, close-contact settings and crowded spaces - while urging them to add in duration and volume considerations.

"I don't think we'll eradicate coronavirus ever, I think it's going to be with humankind forever.

"I think we may get to a point where coronavirus becomes a seasonal problem... possibly flu is the kind of way we would learn to live with it. Do I think there will come a big moment where we have a massive party and throw our masks and hand sanitiser? No I don't. Those habits will perhaps persist for many years. And that may be a good thing if we do."

The Telegraph
2nd December 2020

https://www.telegraph.co.uk/global-health/science-and-disease/coronavirus-news-covid-tier-system-lockdown-new-rules-vaccine/

Malaysia will observe the effectiveness level, side effects and quality of the Covid-19 vaccine for use in the United Kingdom (UK) before deciding on a Covid-19 vaccine for Malaysia, said Health director-general Tan Sri Dr Noor Hisham Abdullah.
---------------------------------------------------------
Dr Noor Hisham said if the vaccine used in the UK shows promising results and has low documentation of side effects in the first three months, this will convince Malaysia to use the vaccine.

"Whatever happens, we will wait for the phase three clinical test report which we have yet to see or study and we need the data before any decision is made.

He said the UK is the first country to allow the emergency use of the Covid-19 vaccine and the country is expected to receive delivery of 40 million doses.

"So we have time to see how the vaccine works among the population in the UK and maybe other countries will also get their respective regulatory authorities to adopt the clause for emergency use of a vaccine which has not been licenced.

@yfhew1- glad you are back after a long absence.

Yup , in case of emergency- Use condom bro.Safety first. LOL

Huat arrr Supermaxx.

------------------------------
Posted by yfhew1 > Dec 2, 2020 10:54 AM | Report Abuse

Safetyfirst, shld buy Karex, condom, sure safety first

SUPERMAX is SMETA/SEDEX Compliant.
----------------------------------

SEDEX is one of the world’s leading ethical trade service providers, working to improve working conditions in global supply chains. It provides practical tools, services and a community network to help companies improve their responsible and sustainable business practices, and source responsibly.

SMETA is an ethical audit format which reports on Sedex's four pillars of labour, health, safety and environment in reflecting good business ethics.

The Supermax Group is fully committed towards social compliance and strives to ensure that there are no forced labour practices at its factories and have implemented various initiatives towards this end. To validate the efforts put in and the progress made, the company had in 2018 commissioned and successfully undergone a SMETA audit conducted by independent international auditors as mentioned in the preceding slide.

Existing policies and procedures are constantly being reviewed for gaps if any and for further improvements. As part of efforts to improve further, the Group is looking into engaging an internationally accredited consulting firm to provide guidance on further best practices.Supermax has commissioned and undergone a Sedex Members Ethical Trade Audit (SMETA) audit by an independent auditor successfully and admitted as a member of SEDEX.

Funds has no where else to go except to the GLOVES sector.

The only bright sector for at least another 2 years or so.

Other sectors will be languished is negative growth for a considerable length of time.

SUPERMAX is the top pick- The illuminating GEM at BURSA in the foreseeable future.

A massive rerating is imminent.

Malaysia's glove makers struggle to meet booming demand
----------------------------------------------------
By AFP

PARIS: With no end in sight to the coronavirus pandemic, worldwide demand for surgical gloves – as for other types of personal protective equipment – is booming, leaving manufacturers struggling to keep up.

The global PPE market – from masks, gowns and gloves, to shoes and sanitising gels – is expected to balloon from US$52 billion in 2019 to US$93 billion in 2027, according to German market data specialist, Statista.

Will SUPERMAX join FBM KLCI?
----------------------------------
The answer is a resounding YES.

According to the news, the next KLCI review result is due on Dec 3 and the changes will be effective on Dec 21.

Analysis revealed that Supermax is likely to be included in KLCI.

It is noted that Supermax had risen to the 24th position, hence qualifying to be included into the index.

As many would know, the share price of Supermax should increase by at least 10% in December-January.

With that said, to those who are holding Supermax- Just HOLD and be patient- TP of RM15 is not a problem by the 2nd qtr of 2021.


P/S

AGM WILL BE HELD ON THE 2ND DECEMBER.

ONLY COMPLETE FOOLS /CLOWNS WILL IMPOSE WINDFALL TAX ON GLOVES
------------------------------------------------------------------

Tengku Zafrul said should the windfall tax be imposed, it would make investors think twice before investing in the country, or even opt to invest in the neighbouring countries like Vietnam and Singapore which do not impose such taxes. "Name me one country in this region that has imposed a windfall tax. “

BREAKING NEWS-

CONFIRMED NO WINDFALL TAX- TENGKU ZAFRUL
-------------------------------
Finance Minister, Zafrul reiterates - NO Windfall tax on glove makers.

This will only send wrong signal to investors.

ECONOMY

Sunday, 29 Nov 2020

SEVERAL groups today called upon the Government to explain its rush in signing a deal to purchase Pfizer’s COVID-19 vaccine despite several unanswered questions.
--------------------------------------------------------------------
“First up, are they proven to be safe and effective on people? Or are we just going treat people as guinea pigs?” the Malaysian Pharmaceutical Society president Amrahi Buang told FocusM.“There has been a lot of controversy in the Western media and scientific & medical circles on the safety of Pfizer’s GMO vaccine, partly due to the rush job in the clinical trials.

“Even if there are no harmful side effects today, what assurance is there that the side effects would not appear in a year’s time?” asked its spokesperson Azmi Anshar.

He added that the vaccine does not prevent COVID-19 transmission of the virus from human to human, only suppressing its symptoms.



“It should not even be called a vaccine, if that is the case,” said Azmi





https://focusmalaysia.my/mainstream/groups-to-govt-why-rush-into-the-pfizer-vaccine-deal/